Article: Other News To Note.

o Accelrys Inc., of San Diego, released the Accord Enterprise Webkit, its latest software solution for chemical and biological information management.

o Biogen Idec Inc., of Cambridge, Mass., said Australian regulatory authorities approved Amevive (alefacept) for sale in that country to treat adult moderate to severe chronic plaque psoriasis patients who are candidates for phototherapy or systemic therapy. Approved in the U.S. early last year, it was the first biologic therapy approved for moderate to severe chronic plaque psoriasis in adults. (See BioWorld Today, Feb. 3, 2003.)

o CalbaTech Inc., of Irvine, Calif., said its wholly owned subsidiary, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!